跳至主要内容
临床试验/NCT05301140
NCT05301140招募中不适用

Vivistim Registry for Paired VNS Therapy (GRASP)

MicroTransponder Inc.17 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 2023年3月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
1,000
试验地点
17
主要终点
Fugl Meyer Assessment (FM-A)

研究概览

简要总结

The purpose of the Vivistim Registry for Paired VNS Therapy (GRASP) is to gather real-world information on patients with arm and hand deficits post-stroke who are considering Vivistim System treatment. Before and after Vivistim System implant, patient data will be collected and reported throughout the therapy process. Physicians or sites will receive appropriate remuneration for the effort and cost involved in collecting and transmitting this data to MicroTransponder Inc.

详细描述

The registry is a data repository of information on patients considering implant of the Vivistim System. The Vivistim System is an FDA approved (P210007) device used to help improve upper limb motor deficits after a stroke. Most patients entered into the registry will go on to be implanted with the System although those who decide not to move forward with the implant procedure can still have data collected as a non-implant comparison group (as long as either or both FM-A / WMFT assessments were collected). The primary purpose of the registry is to provide real-world usage and outcomes data on the Vivistim System. The patient outcome registry will collect acute and long-term follow-up data on Vivistim implanted patients treated with Paired Vagus Nerve Stimulation (Paired VNS™) post-FDA approval.

Historical and implant information as well as quality of life information will be gathered on patients who consider implant of the Vivistim® System. Data will be collected at baseline, 3, 6, and 12 months after implantation, as well as yearly thereafter for up to three (3) years post-implant. Patients who decide not to have the Vivistim System implanted can continue to have data collected for comparison purposes.

Contributing sites and physicians will have access to their own site data and can have anonymized summary analyses on all aggregated data; sites will not have access to other sites' individual level data. Physicians can then use the above information to facilitate patient selection and treatment. Publication (oral or written) of data in the registry, other than individual site data, will not be permitted without the express written advance approval of MicroTransponder, Inc. and the other physicians contributing to the dataset.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients implanted with the Vivistim System for upper limb deficits associated with an ischemic stroke

排除标准

  • Not eligible for surgery

结局指标

主要结局

Fugl Meyer Assessment (FM-A)

时间窗: 6 months

Change in Fugl Meyer Assessment score

Wolf Motor Function Test (WMFT)

时间窗: 6 months

Change in Wolf Motor Function Test score

次要结局

  • Motor Activity Log (MAL)(6 months)
  • Stroke Impact Scale (SIS)(6 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (17)

Loading locations...

相似试验